<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02018952</url>
  </required_header>
  <id_info>
    <org_study_id>RC13_0393</org_study_id>
    <nct_id>NCT02018952</nct_id>
  </id_info>
  <brief_title>Ultrasonography Assessment of Septic Arthritis on Native Joint</brief_title>
  <acronym>SEPT'ECHO</acronym>
  <official_title>Ultrasonography Assessment of Septic Arthritis on Native Joint: a Descriptive, Exploratory, Prospective, Multicentric Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to study the interest of ultrasonography among patients with septic&#xD;
      arthritis.&#xD;
&#xD;
      Currently, ultrasonography is useful for detecting small fluid effusions, for examining&#xD;
      otherwise inaccessible joints, such as the hip and for helping the joint aspiration.&#xD;
&#xD;
      Accurate assessment of disease activity and joint damage in septic arthritis is important for&#xD;
      monitoring treatment efficiency and for prediction of the outcome of the disease.&#xD;
&#xD;
      Nowadays, magnetic resonance imaging (MRI) provides better resolution than radiography or&#xD;
      tomography for the detection of joint effusion and for differentiation between bone and soft&#xD;
      tissue infectious. The sensibility is reported to be nearly 100% with a specificity of more&#xD;
      than 75%.&#xD;
&#xD;
      However, MRI is expensive and not rapidly accessible.&#xD;
&#xD;
      Therefore, ultrasonography, a non invasive, painless, inexpensive, and non radiating exam can&#xD;
      be used to assess the presence and extent of inflammation, destruction, and tissue response.&#xD;
&#xD;
      The objective is to describe, using ultrasonography, the abnormalities joint structure&#xD;
      influenced the septic arthritis evolution and prognosis.&#xD;
&#xD;
      The investigators hope, at the end of this study, to evaluate ultrasonography interest in&#xD;
      septic arthritis and to establish ultrasonography prognosis factors to predict treatment&#xD;
      efficiency and functional outcome.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abnormalities joint structure influencing the septic arthritis evolution and prognosis</measure>
    <time_frame>15 months</time_frame>
    <description>Ultrasonography description of :&#xD;
synovium aspect : homogeneous, nodular&#xD;
maximum thickness synovium&#xD;
synovium doppler signal (grade 0, 1, 2, 3)&#xD;
presence and aspect of joint effusion : anechoic, hypo/hyperechoic, heterogeneous&#xD;
presence and aspect of bone erosions : single, minimal/deep, multiple, minimal/ deep&#xD;
presence of a synovium partitioning&#xD;
soft tissue aspect : cellulitis, myelitis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The evolution of the abnormalities joint structure using ultrasonography</measure>
    <time_frame>15 months</time_frame>
    <description>To describe the evolution of ultrasonography parameters during the monitoring and to research a link between those ultrasonography parameters and prognostic indicators : ultrasonography parameters at day 0, Day 4, Day 15, and 3 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return delay apyrexia</measure>
    <time_frame>15 months</time_frame>
    <description>To describe the evolution of ultrasonography parameters during the monitoring and to research a link between those ultrasonography parameters and prognostic indicators : Return delay apyrexia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delay of surgical management</measure>
    <time_frame>15 months</time_frame>
    <description>To describe the evolution of ultrasonography parameters during the monitoring and to research a link between those ultrasonography parameters and prognostic indicators : Delay of surgical management.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Normalization of C Reactive Protein levels</measure>
    <time_frame>15 months</time_frame>
    <description>To describe the evolution of ultrasonography parameters during the monitoring and to research a link between those ultrasonography parameters and prognostic indicators : Normalization of C Reactive Protein levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of range of motion at 3 months</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of decreased range of motion relative to normal range of motion at 3 months</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at rest measured by scale at 3 months</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain during activity measured by scale at 3 months</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome score Short Form (SF) 36 at 3 months</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Septic Arthritis</condition>
  <arm_group>
    <arm_group_label>Ultrasonography assessment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ultrasonography assessment</intervention_name>
    <description>All patients will be seen at day 0, day 4, day 15 and at 3 months. These visits are usually programmed. Only monitoring ultrasonography, a non invasive exam, and self-administered questionnaires will be made, additional to standard exams for all patients included (no control group).&#xD;
Day 0 :&#xD;
Information of patient and no opposition getting&#xD;
Clinical exam&#xD;
Laboratory tests&#xD;
Radiography of the targeted joint&#xD;
Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)&#xD;
Day 4 :&#xD;
Clinical exam&#xD;
Laboratory tests&#xD;
Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)&#xD;
Day15 :&#xD;
Clinical exam&#xD;
Laboratory tests&#xD;
Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)&#xD;
M3 :&#xD;
Clinical exam&#xD;
Laboratory tests&#xD;
Radiography of the targeted joint&#xD;
Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)&#xD;
Functional outcome</description>
    <arm_group_label>Ultrasonography assessment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Major patients hospitalized in Rheumatology, Infectiology, Orthopedy Department&#xD;
             (hospital of Nantes, of La Roche sur Yon and of Saint-Nazaire) with a septic arthritis&#xD;
             of shoulder, or elbow, or wrist , or hip, or knee, or ankle on native joint, with&#xD;
             positive microbiologic culture joint fluid or positive hemoculture; the diagnosis was&#xD;
             based on positive histology or imagery with an inflammatory joint fluid if the&#xD;
             microbiologic cultures (hemoculture or joint effusion) were negative.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of material on the targeted joint&#xD;
&#xD;
          -  Age &lt; 18 years old&#xD;
&#xD;
          -  Patients under guardianship&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoît LE GOFF, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Grégoire CORMIER, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>CHD La Roche sur Yon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oriane MEROT, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH Saint-Nazaire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH La Roche-sur-Yon</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Saint-Nazaire</name>
      <address>
        <city>Saint-Nazaire</city>
        <zip>44600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>December 11, 2013</study_first_submitted>
  <study_first_submitted_qc>December 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2013</study_first_posted>
  <last_update_submitted>March 24, 2016</last_update_submitted>
  <last_update_submitted_qc>March 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Septic arthritis</keyword>
  <keyword>Ultrasonography</keyword>
  <keyword>Prognosis parameters</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Infectious</mesh_term>
    <mesh_term>Arthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

